Exciting Insights from Leading Experts at the R&D Day
Join us for a compelling virtual Research & Development Day hosted by Bright Minds Biosciences, focusing on absence epilepsy, a condition that significantly affects many lives. During this event, on an upcoming Tuesday, renowned Key Opinion Leaders (KOLs) will provide valuable insights into absence seizures, discussing their complexities and the urgent need for innovative treatments.
Key Speakers at the Event
Highlighted by their significant contributions to neurology and epilepsy research, the featured speakers will include:
Dennis Dlugos, MD
Dr. Dlugos, a leader in pediatric neurology, holds a prestigious position as a professor at the University of Pennsylvania School of Medicine and is deeply involved in advancing the understanding of epilepsy through clinical neurophysiology. His dedication to uncovering the intricate details of absence epilepsy has led to numerous publications, enriching the field with his knowledge.
Wendyl D’Souza, MBChB, MPH, FRACP, PhD
With over two decades of experience, Professor D’Souza brings a wealth of knowledge in managing epilepsy. As the head of Epilepsy Services at St Vincent’s Hospital, he has focused on idiopathic generalized epilepsies and psychogenic non-epileptic attacks. His research efforts aim to enhance treatment strategies and improve patient outcomes, marking him as a key figure for this discussion.
Alexander Rotenberg, MD, PhD
Dr. Rotenberg is recognized for his innovative approaches to epilepsy treatment, particularly through neuromodulation techniques. At Boston Children’s Hospital, he has developed methods such as transcranial magnetic stimulation, aiming to offer new hope for patients with drug-resistant seizures. His groundbreaking work promises to shed light on the potential of non-invasive brain stimulation in treating these challenging conditions.
Introducing Breakthrough Studies
During the talk, Bright Minds' leadership will delve into their ongoing clinical trials, including the BREAKTHROUGH study. This trial is crucial as it assesses the safety and efficacy of BMB-101 in treating classic absence epilepsy and related disorders. Attendees can anticipate interactive discussions, making the event informative and engaging.
Join Us for This Enlightening Experience
Those interested in the forefront of epilepsy research and treatment are encouraged to attend this virtual event. It'll not only provide direct insights from leading specialists but also an opportunity to engage in discussions about emerging therapies that could potentially transform lives. With critical advancements underway, it’s an event you will not want to miss.
About Bright Minds Biosciences
Bright Minds Biosciences is at the cutting-edge of biotechnology, focusing on creating innovative therapies for neurological conditions. Their drug development targets essential brain receptors, striving to address unmet medical needs in epilepsy and related disorders. The company is committed to creating breakthrough therapies designed to significantly enhance patients’ lives.
Frequently Asked Questions
What is the focus of Bright Minds Biosciences R&D Day?
The R&D Day focuses on absence epilepsy, highlighting insights from leading experts in the field.
Who are the featured speakers?
Featured speakers include Dr. Dennis Dlugos, Professor Wendyl D’Souza, and Dr. Alexander Rotenberg, all renowned in their fields.
What is the BREAKTHROUGH study?
The BREAKTHROUGH study is an open-label Phase 2 clinical trial that evaluates the safety and efficacy of BMB-101, specifically targeting classic absence epilepsy.
How can participants access the virtual R&D Day?
Participants can access the event through the Bright Minds website by navigating to the ‘Investors’ section to find 'Events and Presentations.'
What is Bright Minds' overarching mission?
Bright Minds aims to develop transformative therapies for patients suffering from neurological and psychiatric disorders, addressing significant medical needs.
